Skip to main content
Login
Contact
Subscribe
Search form
Search
The Borger News-Herald
Home
Forms
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Calendar
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Amag Pharmaceuticals
(NQ:
AMAG
)
13.75
USD
UNCHANGED
Last Price
Updated: 4:06 PM EST, Nov 13, 2020
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Amag Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
AMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy
May 15, 2017
Transactions extend maturities and reduce total debt by approximately 18%
From
GlobeNewswire News Releases
AMAG Pharmaceuticals to Host Analyst Day on May 24th in New York
May 10, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 24, 2017 from 8:30 a.m. to 12:00 p.m. Eastern Time. Members of...
From
GlobeNewswire News Releases
AMAG Pharmaceuticals Announces Pricing of $300 Million of 3.25% Convertible Senior Notes Due 2022
May 05, 2017
AMAG Pharmaceuticals, Inc. (“AMAG”) (Nasdaq:AMAG) today announced the pricing of $300 million aggregate principal amount of 3.25% Convertible Senior Notes due 2022 (the "notes") in an underwritten...
From
GlobeNewswire News Releases
AMAG Pharmaceuticals Announces Proposed Offering of $250 Million of Convertible Senior Notes due 2022
May 03, 2017
AMAG Pharmaceuticals, Inc. (“AMAG”) (Nasdaq:AMAG) today announced that it intends to offer, subject to market and other conditions, $250 million aggregate principal amount of Convertible Senior Notes...
From
GlobeNewswire News Releases
AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update
May 02, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the quarter ended March 31, 2017. Total GAAP revenue for the first quarter of 2017 increased to...
From
GlobeNewswire News Releases
AMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study
May 02, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced positive top-line results from a Phase 3 randomized, double-blind, non-inferiority clinical trial evaluating Feraheme® (ferumoxytol) compared to...
From
GlobeNewswire News Releases
Investor Network: AMAG Pharmaceuticals, Inc. to Host Earnings Call
May 02, 2017
From
ACCESSWIRE
AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
April 26, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in a fireside chat at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 2:50...
From
GlobeNewswire News Releases
AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance
April 25, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Arpad Simon, M.D., to the role of vice president of pharmacovigilance. Dr. Simon has worked in the pharmaceutical industry...
From
GlobeNewswire News Releases
AMAG Pharmaceuticals to Host First Quarter 2017 Financial Results Conference Call and Webcast on Tuesday, May 2, 2017 at 8:00 a.m. ET
April 19, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2017 financial results will be released on Tuesday, May 2, 2017 before the U.S. financial markets open. Management will...
From
GlobeNewswire News Releases
Research Reports Initiation on Diagnostic Substances Stocks -- Palatin Technologies, AMAG Pharma, IDEXX Labs, and Meridian Bioscience
April 19, 2017
From
PR Newswire
AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use
April 17, 2017
FDA Decision Anticipated on sNDA filing in the Fourth Quarter 2017
From
GlobeNewswire News Releases
AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S. Rights to Intrarosa™ (Prasterone)
April 04, 2017
Anticipated U.S. launch in mid-2017
From
GlobeNewswire News Releases
AMAG Pharmaceuticals to Present at the Needham Healthcare Conference
March 28, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET.
From
GlobeNewswire News Releases
Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
March 20, 2017
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and...
From
PR Newswire
Healthcare Stocks on Investors' Radar -- Delcath Systems, Palatin Technologies, AMAG Pharma, and IDEXX Laboratories
March 14, 2017
From
PR Newswire
AMAG Announces Management Changes and New Commercial Appointments
March 06, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced changes to the company’s executive and commercial leadership teams, including that Frank Thomas, president and chief operating officer, intends...
From
GlobeNewswire News Releases
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
March 01, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
From
GlobeNewswire News Releases
AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting
February 27, 2017
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) together with Palatin Technologies, Inc. (NYSE MKT:PTN) announced that additional results from the Phase 3 RECONNECT Studies (301, 302) of Rekynda™...
From
GlobeNewswire News Releases
AMAG Reports Fourth Quarter and Full Year 2016 Financial Results
February 13, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2016.
From
GlobeNewswire News Releases
AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)
February 13, 2017
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) and Endoceutics, Inc. today announced that they have entered into an exclusive license agreement that provides AMAG with U.S. commercial rights to Intrarosa™...
From
GlobeNewswire News Releases
AMAG Pharmaceuticals to Present at Upcoming Investor Conference
February 09, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Leerink Partners Global Healthcare Conference on Thursday, February 16,...
From
GlobeNewswire News Releases
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Tuesday, February 14, 2017 at 8:00 a.m. ET
February 07, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will report financial results for the fourth quarter and year ended December 31, 2016 on Tuesday, February 14, 2017 before the U.S....
From
GlobeNewswire News Releases
Research Reports Initiation on Healthcare Stocks -- Palatin Technologies, AMAG Pharma, IDEXX Labs, and Delcath Systems
February 06, 2017
From
PR Newswire
AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide)
February 03, 2017
Anticipated new drug application (NDA) filing in early 2018
From
GlobeNewswire News Releases
Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™
February 02, 2017
Will Also Report Second Quarter 2017 Results and Discuss Next Steps in its Development Programs
From
PR Newswire
AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration
February 02, 2017
Supplemental new drug application on track for second quarter 2017 filing
From
GlobeNewswire News Releases
Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™
January 10, 2017
Will Discuss Development of Other Programs
From
PR Newswire
Stock Reports for AMAG Pharmaceuticals, Inc., Acuity Brands, Five Below Inc., Medtronic and Morgan Stanley include trade ideas that offer returns of 22% or more!
January 10, 2017
InvestorsObserver issues critical PriceWatch Alerts for AMAG, AYI, FIVE, MDT, and MS.
From
PR Newswire
AMAG Pharmaceuticals Provides Financial and Business Update
January 09, 2017
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today provided a business update, including announcing preliminary unaudited fourth quarter and annual 2016 financial results, 2017 financial guidance, and an...
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
